Additional Paid-In Capital
Gilead Sciences Additional Paid-In Capital increased by 4.2% to $9.31B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.3%, from $8.14B to $9.31B. Over 5 years (FY 2020 to FY 2025), Additional Paid-In Capital shows an upward trend with a 18.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful equity financing or the exercise of stock options by employees, reflecting capital infusion into the business.
Detailed definition
This represents the amount of capital received from shareholders in excess of the par value of the issued common or pref...
Peer comparison
Commonly high in growth-oriented biopharma companies that have historically raised significant capital to fund R&D and acquisitions.
additional_paid_in_capitalHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.27B | $4.49B | $4.66B | $4.87B | $5.03B | $5.23B | $5.55B | $5.79B | $6.01B | $6.28B | $6.5B | $6.81B | $7.02B | $7.33B | $7.7B | $8.14B | $8.37B | $8.68B | $8.93B | $9.31B |
| QoQ Change | — | +5.2% | +3.8% | +4.4% | +3.4% | +3.9% | +6.2% | +4.4% | +3.7% | +4.5% | +3.5% | +4.8% | +3.1% | +4.3% | +5.1% | +5.7% | +2.8% | +3.7% | +2.9% | +4.2% |
| YoY Change | — | — | — | — | +17.8% | +16.3% | +19.1% | +19.0% | +19.4% | +20.1% | +17.1% | +17.6% | +16.9% | +16.7% | +18.5% | +19.4% | +19.2% | +18.4% | +16.0% | +14.3% |
Additional Paid-In Capital at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's additional paid-in capital?
- Gilead Sciences (GILD) reported additional paid-in capital of $9.31B in Q1 2026.
- How has Gilead Sciences's additional paid-in capital changed year-over-year?
- Gilead Sciences's additional paid-in capital increased by 14.3% year-over-year, from $8.14B to $9.31B.
- What is the long-term trend for Gilead Sciences's additional paid-in capital?
- Over 5 years (2020 to 2025), Gilead Sciences's additional paid-in capital has grown at a 18.1% compound annual growth rate (CAGR), from $3.88B to $8.93B.
- What does additional paid-in capital mean?
- The amount of money shareholders paid for stock above its nominal par value.